title: Cognitive effects of antiepileptic drug discontinuation.
abstract: We studied the cognitive effects of antiepileptic drugs (AEDs), by investigating epileptic patients who were seizure-free for a long time and who were undergoing fixed monotherapy. Ninety patients [27 with phenobarbital (PB), 18 with carbamazepine (CBZ), 16 with phenytoin (PHT), and 29 with valproate (VPA)] were examined by a neuropsychological battery exploring intelligence, vigilance, attention, memory, and visuomotor performances at full AED dose (T1) and compared to 28 normal volunteers. We also evaluated the effects of AED discontinuation by retesting patients 3 months after reduction at half drug dose (T2) and 3 months (T3) and 1 year (T4) after complete discontinuation. Our findings showed that patients receiving CBZ did not differ from controls at any time of examination. Patients receiving PB had significant differences only at T1 (visuomotor performance and immediate spatial memory). Patients receiving VPA showed differences in attention, visuomotor performance, verbal span and sensory discrimination tasks at T1, in visuomotor performance at T2 and in spatial span at T3, whereas no differences were detected at T4. Patients receiving PHT had a difference in intelligence and visuomotor performance at T1, in intelligence at T2, and no differences at T3 or T4. This study model is useful for investigating the cognitive effects of AED because it allows selection of a uniform sample, eliminating variables such as type, frequency, and gravity of seizures that complicate this kind of study.
authors: Institute of Neurology, University of Bologna, Italy.
authors: R
authors: R
authors: Gallassi
authors: A
authors: A
authors: Morreale
authors: R
authors: R
authors: Di Sarro
authors: M
authors: M
authors: Marra
authors: E
authors: E
authors: Lugaresi
authors: A
authors: A
authors: Baruzzi
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000494:pharmacology; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000139:chemically induced / Q000175:diagnosis; D004827:Epilepsy / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008875:Middle Aged; D009483:Neuropsychological Tests; D010634:Phenobarbital / Q000009:adverse effects / Q000494:pharmacology; D010672:Phenytoin / Q000009:adverse effects / Q000494:pharmacology; D011597:Psychomotor Performance / Q000187:drug effects; D014635:Valproic Acid / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital